주메뉴 바로가기 본문 바로가기

LigaChem Biosciences logo LigaChem Biosciences logo(black) 메인으로 이동

For Tomorrow, LigaChemBio

Korean English
About Us
Dedicated to revolutionizing new drug discovery and development

History

More than 15 years of dedication to revolutionizing new drug therapies
2024
  • 03.
    Changed company name to 'LigaChem Biosciences'
  • 03.
    PAN Orion Corp. Limited became the largest shareholder
  • 10.
    Signed a package deal with Ono Pharmaceutical for LCB97 (L1CAM-ADC) and a platform licensing deal for developing multi-target ADCs
  • 11.
    Winner of 'Best ADC Platform Technology' award for three consecutive years at the World ADC Awards 2024
  • 12.
    LNCB74(B7-H4 ADC) received IND approval for Phase 1 clinical trial from the U.S. FDA.
  • 12.
    LCB71(ROR1-ADC) global Phase 1b clinical trial initiated by CStone
2023
  • 06.
    IND approval for LCB84 (TROP2-ADC) Phase 1/2 trials
  • 12.
    Licensing partnership with J&J for LCB84 (TROP2-ADC)
  • 10.
    Winner of the 'Best ADC Platform Technology' award at the World ADC Awards 2023
  • 10.
    LCB14 (HER2-ADC) global Phase 1a clinical trial initiated by IKSUDA
2022
  • 01.
    Approval of LCB14 (HER2 ADC) for Phase 2 Clinical Trial in China
  • 03.
    Established 'AntibodyChem Bioscienses', a subsidiary in Boston, USA
  • 11.
    Co-Developement Partnership with Nextcure to develop B7-H4 ADC
  • 11.
    Delpazolid designated Orphan Drug by EMA
  • 11.
    SOTIO Exercises Option for the Development of a Novel ADC
  • 12.
    Licensing partnership with AMGEN for Multi-Target ADC Research Collaboration and Development
2021
  • 06.
    Iksuda Enter Into a expansion of License Agreement to further develop ADC
  • 10.
    Winner of 'Best ADC Platform Technology' at World ADC Awards 2021
  • 11.
    LCB and Sotio Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of ADC
  • 12.
    LCB and IKSUDA enter Co-development & License Agreement for LCB14 (HER2-ADC)
2020
2019
2018
  • 01.
    LCB enters into third party Licensing agreement with Lee's Pharm for LCB02-0133
  • 01.
    Delpazolid designated for Fast Track by US FDA
2017
  • 08.
    Japanese patent registration on the unique ADC platform technology ConjuALL
  • 07.
    Delpazolid designated for Orphan Drug by US FDA
  • 05.
    LCB enters into third party Licensing agreement with BridgeBio for BBT-877
  • 04.
    US patent registration on the unique ADC platform technology ConjuALL
  • 01.
    Patent acquisition on LegoChem Bio, ADC antibody structure and manufacturing method
  • 01.
    LCB enters into research licensing agreement with Takeda
2016
  • 12.
    LCB enters licensing agreement with RMX Biopharma for LCB01-0371 (gram-positive antibiotic) regarding China market.
  • 08.
    LCB Initiates clinical trial phase I of oxazolidinone antibiotic LCB01-0371 (IV)
  • 07.
    LCB sets up a Joint Venture for the global development of Cephalosporin antibiotic LCB10-0200
  • 06.
    LCB obtains patent for its novel linker chemistry (Compounds Comprising Self-immolative group)
  • 05.
    LCB initiates clinical trial phase II of oxazolidinone antibiotic LCB01-0371 (PO)
  • 05.
    Mechanical completion of API Plant I (LegoChem Pharma)
  • 08.
    LCB extends designation as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy
2015
  • 12.
    Acquisition of Khanmed & Hanbul Pharma
  • 11.
    LCB enters into a Joint Research agreement with Theranyx
  • 08.
    LCB licenses out anti-Her2 ADC to Fosun Pharma for the Greater Chinese market
2014
  • 10.
    LCB01-0371 (oxazolidinone antibiotic) is selected as a “PHARM NAVI” project by the MFDS (Ministry of Food and Drug Safety)
  • 09.
    Completion of clinical trial phase 1 for LCB02-0133 (FXa, Anti-Coagulant Candidate)
  • 08.
    LCB is designated as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy.
2013
  • 08.
    LCB Initiates pre-clinical trial of cephalosporin antibiotic LCB10-0200
  • 07.
    LCB’s ADC (Antibody Drug Conjugate) is selected as an investment related project by the Small and Medium Business Administration (SMBA).
  • 05.
    LCB (141080) is listed on KOSDAQ through Initial Public Offering
2012
  • 12.
    LCB enters into a collaboration agreement with AstraZeneca and license out its cephalosporion antibiotic candidate LCB10-0200
  • 12.
    LCB enters into a collaboration agreement with Green Cross to develop Next-generation Antibody-Drug Conjugates
  • 07.
    LCB enters into a collaboration agreement with Sanofi to develop novel oncologics
  • 06.
    LCB designated as an INNO-BIZ company
  • 03.
    CB named as “Emerging Company of the Year 2012” (BioSpectrum Aisa, Singapore)
  • 02.
    LCB initiates clinical trial phase I of FXa inhibitor anti-coagulant candidate LCB02-0133
2011
  • 11.
    US FDA IND approval for anti-coagulant candidate LCB02-0133
  • 07.
    LCB02-0133(Anit-coagulant, FXa inhibitor) selected as Global New Drug Discovery Project by Korean Ministry of Education, Science, and Technology
2010
  • 12.
    Completed non-clinical trials of an oxazolidinone antibiotic
  • 10.
    Signed a joint research contract on anticancer drugs with Interprotein in Japan (Project title: VEGF inhibitor)
  • 09.
    Presented research findings on antibiotics at 2010 ICAAC in Boston, United States
2009
  • 12.
    LCB presents antibiotic study result at the 2009 “ICAAC” San Francisco
  • 06.
    LCB successfully license-out its preclinical stage Anti-coagulant candidate LCB02-0133 (FXa inhibitor)
  • 01.
    Joint research contract with The Catholic Univ. School of Medicine (ophthalmic medicine: Wondonin) is executed
2008
  • 05.
    LCB receives Korean MOHW (Ministry of Health and Welfare) researching funding for oxazolidinone antibiotic candidate.
2007
  • 09.
    LCB presents oxazolidinone antibiotic study result at the Chicago “ICAAC” Conference 2007
2006
  • 05.
    LCB is founded